Alantra is pleased to announce it has advised Trill Impact, who aims to be a thought leader and force for positive change through impact private investments, on its partnership with TT medic Group, a developer, manufacturer, and cleanroom processor of high-quality plastic components for the life science industry.
Korbinian Knoblach, Partner and Co-Head of Private Equity at Trill Impact Advisory, says: “We were impressed by TT medic’s position as an integrated partner of its global OEM customers, often acknowledged as part of the product development team within their specialized field of high-quality polymers. Trill Impact is looking forward to building on the successful growth of TT medic in our joint partnership.”
Christopher Jobst, Managing Director at Alantra and Head of the Healthcare team in Germany, said: “We are delighted to have supported Trill Impact. We provided detailed valuation and competitor analyses as well as an in-depth assessment of alternative exit options and potential add-on opportunities. This transaction marks another addition to Alantra’s broad expertise in the European MedTech (CDMO) space.”
Christoph Handrup, Managing Director at Alantra’s Frankfurt office, added: “We would also like to thank Trill Impact for their continuous trust and close cooperation. Our sector knowledge and the integrated team approach of M&A and Debt Advisory enabled us to optimally support the Trill Impact team. We are convinced that Trill Impact together with the TT Medic management team, reinvesting shareholders and industry experts will successfully drive the Company’s further growth supported by Trill Impacts experience in the development of founder-led businesses.”
Alantra’s role consisted of full scope M&A and Debt Advisory, which in its view, increased transaction security for Trill Impact but also for TT Medic.
Read more: https://lnkd.in/dRgdBtbv
#LifeSciences #MedTech #MandA #HealthcareInnovation #InvestmentBanking
